COCP waking up??

Taken From, Corporate Presentation

June 2018

Nobel Prize winning expertise leveraged to design first- and best-in-class antiviral drug

candidates addressing well established and growing markets


• Lead program CC-31244 for the treatment of hepatitis C infection entering Phase 2a in Q2 2018


‐ Received IND clearance from FDA in Q1 2018

‐ Topline data expected before year end

‐ Exploring partnering opportunities in strategic territories
 
• Influenza candidate, CC-42344 is a novel PB2 inhibitor scheduled to enter Phase 1 in Q4 2018

for the treatment of influenza


‐ Shown excellent antiviral activity against influenza A strains, including avian pandemic strains and

Tamiflu resistant strains


• Company positioned to achieve multiple clinical and regulatory milestones in the near-term


• Recently uplisted to Nasdaq Capital Market (Cocrystal Pharma Announces Nasdaq Closing Bell Ceremony June 4,2018)


Selected Value Indicators Suggest

Potential Significant Upside


Company Name                            Ticker    Market Cap (M)*                      Overview Status



Arrowhead Pharmaceuticals        ARWR     $938                   Develops medicines to treat intractable diseases by silencing the

                                                                                                 genes that cause them

                                                                                                 2 Phase 1

                                                                                                 6 Preclinical


Arbutus BioPharma                      ABUS       $323                  Biopharmaceutical company developing a cure for patients

                                                                                                suffering from chronic hepatitis B infection

                                                                                                1 Phase 2

                                                                                                2 Preclinical

                                                                                                3 Discovery


Chimerix                                      CMRX        $218                  Developing novel antivirals for the growing population of

                                                                                                 immunocompromised patients,

                                                                                                1 Phase 3

                                                                                                2 Phase 2

                                                                                                1 Phase 1


Sinovac Biotech                           SVA          $445                  Biopharmaceutical company that develops vaccines that protect

                                                                                                against human infectious diseases

                                                                                               1 NDA post Phase 3 preliminary data

                                                                                               1 IND approval

                                                                                               2 IND filed


Spring Bank Pharmaceuticals     SBPH        $178                 Discovery and development of a novel class of therapeutics

                                                                                               using a proprietary small molecule nucleic acid hybrid, or SMNH

                                                                                               2 Phase 2

                                                                                               3 Preclinical



Financial Snapshot – Nasdaq: COCP


Market cap*
            $67.3MM
   Based on May 31, 2018 closing price of $2.25 per share.

Common shares
        29.9MM

outstanding


Average daily

volume**                  60K
           Based on May 31, 2018 Yahoo Finance.

Crusher

Yeah, and it's getting the same treatment OPK gets every day around this time.

Its down over 50 percent from the reverse  split . Can you explain were the double is ?

I got really lucky with this stock, many years ago. It ran from about 30 cents to $1.51.. I had 150K shares, sold most of it for about $1.30.. think I cleared $80K on the deal.

Am way under-water on this 5K shares, but think it will be just fine - one drug will make it well.

C L